Cilostazol

Chemical formula: C₂₀H₂₇N₅O₂  Molecular mass: 369.461 g/mol  PubChem compound: 2754

Therapeutic indications

Cilostazol is indicated for:

Intermittent claudication

Population group: only adults (18 years old or older)

Cilostazol is indicated for the improvement of the maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II).

Cilostazol is for second-line use, in patients in whom lifestyle modifications (including stopping smoking and [supervised] exercise programs) and other appropriate interventions have failed to sufficiently improve their intermittent claudication symptoms.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cilostazol is contraindicated in the following cases:

Pregnancy

Pregnancy

Severe renal impairment (creatinine clearance of ≤25 ml/min)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Moderate or severe hepatic impairment

at least one of
Hepatic failure stage III
Hepatic failure stage IV

Congestive heart failure

Congestive heart failure

Predisposition to bleeding, peptic ulceration, haemorrhagic stroke, diabetic retinopathy, uncontrolled hypertension

at least one of
At risk of hemorrhage
Peptic ulcer
Intracranial hemorrhage
Proliferative diabetic retinopathy
Hypertensive crisis

Ventricular tachycardia, ventricular fibrillation, multifocal ventricular ectopics, prolongation of the QTc interval

at least one of
Ventricular tachycardia
Ventricular fibrillation
H/O ventricular fibrillation
Electrocardiogram: ectopic beats with multifocal premature ventricular contractions
† Ventricular premature beats
Prolonged QT interval
Long QT syndrome

Tachyarrhythmia

Tachyarrhythmia

Unstable angina pectoris, myocardial infarction, coronary intervention

at least one of
Preinfarction syndrome
Myocardial infarction
Recent myocardial infarction
Procedure on coronary arteries

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: CILOSTAZOL Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈